Role of IL-13 in systemic sclerosis

Cytokine

Volumn 56, Issue 3, 2011, Pages 544-549

  Fuschiotti, Patrizia ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Fibrosis; GATA 3; Human; IL 13

Indexed keywords

BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 33; INTERLEUKIN 4; MESSENGER RNA; SMALL INTERFERING RNA; STAT6 PROTEIN; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR ALPHA;

CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EFFECTOR CELL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INTERLEUKIN 13 GENE; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC SCLEROSIS; TH2 CELL; TRANSCRIPTION FACTOR GATA 3 GENE; TRANSCRIPTION REGULATION;

HUMANS; INTERLEUKIN-13; MODELS, IMMUNOLOGICAL; SCLERODERMA, SYSTEMIC; T-LYMPHOCYTES;

EID: 81455158849     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.08.030     Document Type: Review

References (113)

1. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
2. Stephanie Gu Y., Kong J., Cheema G.S., Keen C.L., Wick G., Gershwin M.E. The Immunobiology of Systemic Sclerosis. Semin Arthritis Rheum 2008.
3. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567.
4. Mayes M.D. Scleroderma epidemiology. Rheum Dis Clin North Am 2003, 29:239-254.
5. Medsger T.A. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003, 29:255-273. vi.
6. Medsger T.A. Classification prognosis. Systemic sclerosis 2004, 17-28. Lippincott Williams & Williams, Philadelphia. 2nd ed. P.J. Clements, D.E. Furst (Eds.).
7. Steen V.D., Medsger T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43:2437-2444.
8. Kissin E.Y., Korn J.H. Fibrosis in scleroderma. Rheum Dis Clin North Am 2003, 29:351-369.
9. Fleischmajer R., Perlish J.S., Reeves J.R. Cellular infiltrates in scleroderma skin. Arthritis Rheum 1977, 20:975-984.
10. Roumm A.D., Whiteside T.L., Medsger T.A., Rodnan G.P. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984, 27:645-653.
11. Giacomelli R., Matucci-Cerinic M., Cipriani P., Ghersetich I., Lattanzio R., Pavan A., et al. Circulating Vdelta1+ T cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 1998, 41:327-334.
12. Sakkas L.I., Xu B., Artlett C.M., Lu S., Jimenez S.A., Platsoucas C.D. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002, 168:3649-3659.
13. Prescott R.J., Freemont A.J., Jones C.J., Hoyland J., Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992, 166:255-263.
14. Kahari V.M., Sandberg M., Kalimo H., Vuorio T., Vuorio E. Identification of fibroblasts responsible for increased collagen production in localized scleroderma by in situ hybridization. J Invest Dermatol 1988, 90:664-670.
15. Whiteside T.L., Buckingham R.B., Prince R.K., Rodnan G.P. Products of activated mononuclear cells modulate accumulation of collagen by normal dermal and scleroderma fibroblasts in culture. J Lab Clin Med 1984, 104:355-369.
16. Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Ann Med 2007, 39:42-53.
17. Atamas S.P., Yurovsky V.V., Wise R., Wigley F.M., Goter Robinson C.J., Henry P., et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999, 42:1168-1178.
18. Distler J.H., Jungel A., Caretto D., Schulze-Horsel U., Kowal-Bielecka O., Gay R.E., et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 2006, 54:214-225.
19. Kuwana M., Medsger T.A., Wright T.M. T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. J Immunol 1995, 155:2703-2714.
20. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005, 35:35-42.
21. Baraut J., Michel L., Verrecchia F., Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010, 10:65-73.
22. Wynn T.A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004, 4:583-594.
23. Denton C.P., Abraham D.J. Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001, 13:505-511.
24. Scala E., Pallotta S., Frezzolini A., Abeni D., Barbieri C., Sampogna F., et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004, 138:540-546.
25. Sato S., Hasegawa M., Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001, 27:140-146.
26. Kurasawa K., Hirose K., Sano H., Endo H., Shinkai H., Nawata Y., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43:2455-2463.
27. Hasegawa M., Fujimoto M., Kikuchi K., Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24:328-332.
28. Denton C.P., Shi-Wen X., Sutton A., Abraham D.J., Black C.M., Pearson J.D. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998, 114:293-300.
29. Cipriani P., Franca Milia A., Liakouli V., Pacini A., Manetti M., Marrelli A., et al. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheum 2006, 54:3022-3033.
30. Distler O., Distler J.H., Scheid A., Acker T., Hirth A., Rethage J., et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004, 95:109-116.
31. Carulli M.T., Ong V.H., Ponticos M., Shiwen X., Abraham D.J., Black C.M., et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005, 52:3772-3782.
32. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998, 16:137-161.
33. Varga J., Whitfield M.L. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci (Schol Ed) 2009, 1:226-235.
34. Varga J., Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009, 5:200-206.
35. Hsu E., Shi H., Jordan R.M., Lyons-Weiler J., Pilewski J.M., Feghali-Bostwick C.A. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum 2011, 63:783-794.
36. Manetti M., Ibba-Manneschi L., Liakouli V., Guiducci S., Milia A.F., Benelli G., et al. The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2010, 69:598-605.
37. Duan H., Fleming J., Pritchard D.K., Amon L.M., Xue J., Arnett H.A., et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008, 58:1465-1474.
38. Distler J.H., Jungel A., Kowal-Bielecka O., Michel B.A., Gay R.E., Sprott H., et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005, 52:856-864.
39. Tsuji-Yamada J., Nakazawa M., Minami M., Sasaki T. Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 2001, 28:1252-1258.
40. Mavalia C., Scaletti C., Romagnani P., Carossino A.M., Pignone A., Emmi L., et al. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am J Pathol 1997, 151:1751-1758.
41. Fujii H., Hasegawa M., Takehara K., Mukaida N., Sato S. Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis. Clin Exp Immunol 2002, 130:548-556.
42. Valentini G., Baroni A., Esposito K., Naclerio C., Buommino E., Farzati A., et al. Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation. J Clin Immunol 2001, 21:210-217.
43. Atamas S.P., White B. Cytokine regulation of pulmonary fibrosis in scleroderma. Cytokine Growth Factor Rev 2003, 14:537-550.
44. Fuschiotti P., Medsger T.A., Morel P.A. Effector CD8+ T cells in systemic sclerosis patients produce abnormally high levels of interleukin-13 associated with increased skin fibrosis. Arthritis Rheum 2009, 60:1119-1128.
45. Hoffmann K.F., McCarty T.C., Segal D.H., Chiaramonte M., Hesse M., Davis E.M., et al. Disease fingerprinting with cDNA microarrays reveals distinct gene expression profiles in lethal type 1 and type 2 cytokine-mediated inflammatory reactions. FASEB J 2001, 15:2545-2547.
46. Sandler N.G., Mentink-Kane M.M., Cheever A.W., Wynn T.A. Global gene expression profiles during acute pathogen-induced pulmonary inflammation reveal divergent roles for Th1 and Th2 responses in tissue repair. J Immunol 2003, 171:3655-3667.
47. Lakos G., Melichian D., Wu M., Varga J. Increased bleomycin-induced skin fibrosis in mice lacking the Th1-specific transcription factor T-bet. Pathobiology 2006, 73:224-237.
48. Aliprantis A.O., Wang J., Fathman J.W., Lemaire R., Dorfman D.M., Lafyatis R., et al. Transcription factor T-bet regulates skin sclerosis through its function in innate immunity and via IL-13. Proc Natl Acad Sci USA 2007, 104:2827-2830.
49. Chomarat P., Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 1998, 17:1-52.
50. Rengarajan J., Szabo S.J., Glimcher L.H. Transcriptional regulation of Th1/Th2 polarization. Immunol Today 2000, 21:479-483.
51. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998, 8:275-283.
52. Hilton D.J., Zhang J.G., Metcalf D., Alexander W.S., Nicola N.A., Willson T.A. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci USA 1996, 93:497-501.
53. Donaldson D.D., Whitters M.J., Fitz L.J., Neben T.Y., Finnerty H., Henderson S.L., et al. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 1998, 161:2317-2324.
54. Wills-Karp M., Finkelman F.D. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 2008, 1:pe55.
55. Wynn T.A. IL-13 effector functions. Annu Rev Immunol 2003, 21:425-456.
56. Kelly-Welch A.E., Hanson E.M., Boothby M.R., Keegan A.D. Interleukin-4 and interleukin-13 signaling connections maps. Science (New York, NY) 2003, 300:1527-1528.
57. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
58. Mentink-Kane M.M., Cheever A.W., Thompson R.W., Hari D.M., Kabatereine N.B., Vennervald B.J., et al. IL-13 receptor alpha 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA 2004, 101:586-590.
59. Andrew D.P., Chang M.S., McNinch J., Wathen S.T., Rihanek M., Tseng J., et al. STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 1998, 161:5027-5038.
60. Lee C.G., Homer R.J., Zhu Z., Lanone S., Wang X., Koteliansky V., et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001, 194:809-821.
61. Lanone S., Zheng T., Zhu Z., Liu W., Lee C.G., Ma B., et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest 2002, 110:463-474.
62. Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006, 12:99-106.
63. Strober W., Kitani A., Fichtner-Feigl S., Fuss I.J. The signaling function of the IL-13Ralpha2 receptor in the development of gastrointestinal fibrosis and cancer surveillance. Curr Mol Med 2009, 9:740-750.
64. Granel B., Allanore Y., Chevillard C., Arnaud V., Marquet S., Weiller P.J., et al. IL13RA2 gene polymorphisms are associated with systemic sclerosis. J Rheumatol 2006, 33:2015-2019.
65. Granel B., Chevillard C., Allanore Y., Arnaud V., Cabantous S., Marquet S., et al. Evaluation of interleukin 13 polymorphisms in systemic sclerosis. Immunogenetics 2006, 58:693-699.
66. Rankin A.L., Mumm J.B., Murphy E., Turner S., Yu N., McClanahan T.K., et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol 2010, 184:1526-1535.
67. Riccieri V., Rinaldi T., Spadaro A., Scrivo R., Ceccarelli F., Franco M.D., et al. Interleukin-13 in systemic sclerosis: relationship to nailfold capillaroscopy abnormalities. Clin Rheumatol 2003, 22:102-106.
68. Fuschiotti P. CD8(+) T cells in systemic sclerosis. Immunol Res 2011, 50:188-194.
69. Falkner D., Wilson J., Fertig N., Clawson K., Medsger T.A., Morel P.A. Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J Rheumatol 2000, 27:1196-1202.
70. Johnson R.W., Tew M.B., Arnett F.C. The genetics of systemic sclerosis. Curr Rheumatol Rep 2002, 4:99-107.
71. Pantelidis P., Jones M.G., Welsh K.I., Taylor A.N., du Bois R.M. Identification of four novel interleukin-13 gene polymorphisms. Genes Immun 2000, 1:341-345.
72. Howard T.D., Whittaker P.A., Zaiman A.L., Koppelman G.H., Xu J., Hanley M.T., et al. Identification and association of polymorphisms in the interleukin-13 gene with asthma and atopy in a Dutch population. Am J Respir Cell Mol Biol 2001, 25:377-384.
73. Vercelli D. Genetics of IL-13 and functional relevance of IL-13 variants. Curr Opin Allergy Clin Immunol 2002, 2:389-393.
74. van der Pouw Kraan T.C., van Veen A., Boeije L.C., van Tuyl S.A., de Groot E.R., Stapel S.O., et al. An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1999, 1:61-65.
75. Kouriba B., Chevillard C., Bream J.H., Argiro L., Dessein H., Arnaud V., et al. Analysis of the 5q31-q33 locus shows an association between IL13-1055C/T IL-13-591A/G polymorphisms and Schistosoma haematobium infections. J Immunol 2005, 174:6274-6281.
76. Cameron L., Webster R.B., Strempel J.M., Kiesler P., Kabesch M., Ramachandran H., et al. Th2 cell-selective enhancement of human IL13 transcription by IL13-1112C>T, a polymorphism associated with allergic inflammation. J Immunol 2006, 177:8633-8642.
77. Agarwal S., Rao A. Modulation of chromatin structure regulates cytokine gene expression during T cell differentiation. Immunity 1998, 9:765-775.
78. Agarwal S., Viola J.P., Rao A. Chromatin-based regulatory mechanisms governing cytokine gene transcription. J Allergy Clin Immunol 1999, 103:990-999.
79. Kaplan M.H., Schindler U., Smiley S.T., Grusby M.J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996, 4:313-319.
80. Takeda K., Tanaka T., Shi W., Matsumoto M., Minami M., Kashiwamura S., et al. Essential role of Stat6 in IL-4 signalling. Nature 1996, 380:627-630.
81. Zheng W., Flavell R.A. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587-596.
82. Brown M.A., Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol 1997, 17:1-32.
83. Casolaro V., Keane-Myers A.M., Swendeman S.L., Steindler C., Zhong F., Sheffery M., et al. Identification and characterization of a critical CP2-binding element in the human interleukin-4 promoter. J Biol Chem 2000, 275:36605-36611.
84. Guo J., Casolaro V., Seto E., Yang W.M., Chang C., Seminario M.C., et al. Yin-Yang 1 activates interleukin-4 gene expression in T cells. J Biol Chem 2001, 276:48871-48878.
85. Ouyang W., Lohning M., Gao Z., Assenmacher M., Ranganath S., Radbruch A., et al. Stat6-independent GATA-3 autoactivation directs IL-4-independent Th2 development and commitment. Immunity 2000, 12:27-37.
86. Ho I.C., Glimcher L.H. Transcription: tantalizing times for T cells. Cell 2002, 109(Suppl):S20-S109.
87. Zhou M., Ouyang W. The function role of GATA-3 in Th1 and Th2 differentiation. Immunol Res 2003, 28:25-37.
88. Lavenu-Bombled C., Trainor C.D., Makeh I., Romeo P.H., Max-Audit I. Interleukin-13 gene expression is regulated by GATA-3 in T cells: role of a critical association of a GATA and two GATG motifs. J Biol Chem 2002, 277:18313-18321.
89. Kishikawa H., Sun J., Choi A., Miaw S.C., Ho I.C. The cell type-specific expression of the murine IL-13 gene is regulated by GATA-3. J Immunol 2001, 167:4414-4420.
90. Farrar J.D., Asnagli H., Murphy K.M. T helper subset development: roles of instruction, selection, and transcription. J Clin Invest 2002, 109:431-435.
91. Medsger TA, Jr., Ivanco DE, Kardava L, Morel PA, Lucas MR, Fuschiotti P. GATA-3 upregulation in CD8+ T cells is a biomarker of immune dysfunction in systemic sclerosis, resulting in excess IL-13 production. Arthritis Rheum, in press.
92. Tan F.K., Zhou X., Mayes M.D., Gourh P., Guo X., Marcum C., et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006, 45:694-702.
93. Paul W.E., Zhu J. How are T(H)2-type immune responses initiated and amplified?. Nat Rev Immunol 2010, 10:225-235.
94. Szabo S.J., Kim S.T., Costa G.L., Zhang X., Fathman C.G., Glimcher L.H. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 2000, 100:655-669.
95. Szabo S.J., Sullivan B.M., Stemmann C., Satoskar A.R., Sleckman B.P., Glimcher L.H. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science (New York, NY) 2002, 295:338-342.
96. Mullen A.C., High F.A., Hutchins A.S., Lee H.W., Villarino A.V., Livingston D.M., et al. Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. Science (New York, NY) 2001, 292:1907-1910.
97. Usui T., Preiss J.C., Kanno Y., Yao Z.J., Bream J.H., O'Shea J.J., et al. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med 2006, 203:755-766.
98. Suzuki K., Kaminuma O., Hiroi T., Kitamura F., Miyatake S., Takaiwa F., et al. Downregulation of IL-13 gene transcription by T-bet in human T cells. Int Arch Allergy Immunol 2008, 146(Suppl 1):33-35.
99. Ho I.C., Pai S.Y. GATA-3 - not just for Th2 cells anymore. Cell Mol Immunol 2007, 4:15-29.
100. Gourh P., Agarwal S.K., Divecha D., Assassi S., Paz G., Arora-Singh R.K., et al. Polymorphisms in TBX21 and STAT4 increase the risk of systemic sclerosis: evidence of possible gene-gene interaction and alterations in Th1/Th2 cytokines. Arthritis Rheum 2009, 60:3794-3806.
101. Needleman B.W., Wigley F.M., Stair R.W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992, 35:67-72.
102. Yoshimoto T., Yasuda K., Tanaka H., Nakahira M., Imai Y., Fujimori Y., et al. Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol 2009, 10:706-712.
103. Kuroiwa K., Arai T., Okazaki H., Minota S., Tominaga S. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun 2001, 284:1104-1108.
104. Au K., Khanna D., Clements P.J., Furst D.E., Tashkin D.P. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep 2009, 11:111-119.
105. Cousins D.J., McDonald J., Lee T.H. Therapeutic approaches for control of transcription factors in allergic disease. J Allergy Clin Immunol 2008, 121:803-809.
106. Finotto S., Hausding M., Doganci A., Maxeiner J.H., Lehr H.A., Luft C., et al. Asthmatic changes in mice lacking T-bet are mediated by IL-13. Int Immunol 2005, 17:993-1007.
107. Finotto S., De Sanctis G.T., Lehr H.A., Herz U., Buerke M., Schipp M., et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001, 193:1247-1260.
108. Zhang D.H., Yang L., Cohn L., Parkyn L., Homer R., Ray P., et al. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 1999, 11:473-482.
109. Chizzolini C. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis. Curr Opin Rheumatol 2008, 20:707-712.
110. Vettori S., Maresca L., Cuomo G., Abbadessa S., Leonardo G., Valentini G. Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. Scand J Rheumatol 2010, 39:485-489.
111. Shore S.A. Direct effects of Th2 cytokines on airway smooth muscle. Curr Opin Pharmacol 2004, 4:235-240.
112. Terrier B., Tamby M.C., Camoin L., Guilpain P., Berezne A., Tamas N., et al. Antifibroblast antibodies from systemic sclerosis patients bind to {alpha}-enolase and are associated with interstitial lung disease. Ann Rheum Dis 2010, 69:428-433.
113. McKenzie A.N., Culpepper J.A., de Waal Malefyt R., Briere F., Punnonen J., Aversa G., et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993, 90:3735-3739.